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BRIEF REPORT

Angiotensin Receptor Blockers Associated
Enteropathy- Brief Report
Neha Gosai a, Falgun Gosai b,*
a
b

Avalon School of Medicine, Curaçao
Adult Hospitalist, SFMC Peoria, Illinois, USA

Abstract
The current literature has shown equivocal results regarding the association of Olmesartan and other angiotensin
receptor blockers (ARBs) use and the presence of Celiac sprue-like enteropathy (CSLE). Various factors affecting the
association are- patient population under study, geographic area, and duration of use of medication. Various case reports/ case series and observational studies have shown the mixed results regarding an association. We have tried to
answer a question what exists in the literature regarding the angiotensin receptor blockers related sprue like enteropathy.
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1. Angiotensin receptor blockers associated
enteropathy- does it really exist?

medication improves not only symptoms but also the
histological features of CSLE.3

T

3. Background of ARBs

he current literature has shown equivocal
results regarding the association of Olmesartan and other angiotensin receptor blockers
(ARBs) use and the presence of Celiac sprue-like
enteropathy (CSLE). Various factors affecting
the association are-patient population under
study, geographic area, and duration of use of
medication.

2. When to suspect celiac sprue-like
enteropathy
The presence of enteropathy symptoms like
chronic diarrhea, malabsorption, and weight loss in
the absence of celiac serology may suggest the possibility of CSLE.1 The laboratory ﬁndings of hypoalbuminemia, electrolyte imbalances, and negative
stool cultures are supportive. The duodenal biopsy
may reveal variable degree of duodenal villous atrophy with increased intra-epithelial lymphocytes or
rarely eosinophils-same as classical celiac sprue.2
The lack of response to gluten-free diet also supports
the diagnosis of CSLE. Discontinuation of the culprit

For the last decade and a half, ARBs have been
widely used for their cardiovascular beneﬁts. In 2010,
a study from Mayo clinic showed that among patients
with CSLE, 25% were on Olmesartan (OM).4 The
subsequent case series and various other studies
have also shown the higher rate of CSLE with various
ARBs use. In 2011, the Food and Drug Administration
(FDA) requested a Mini-Sentinel modular program
report of risk assessment because the number of
cases of CSLE among users of Olmesartan was higher
than expected in the FDA adverse event report system. However, the incidence of CSLE was found to be
similar between all ARBs, including OM.4 Nevertheless, in July 2013, the FDA issued a ‘Drug Safety
Communication’ approving a label change to include
CSLE linked to OM.

4. How do they do it?
Even though, several mechanisms by which ARBs
might increase the risk of enteropathy have been
proposed, the exact mechanism is still unknown.
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Table 1. Studies showing signiﬁcant association of Olmesartan (OM) and CSLE.
Study

Type of study

Biopsy proven
CSLE

Results

Y H Dong et al.9
Mickael Basson et al.10

Retrospective cohort
Prospective

No
No

HR- 1.21(95% CI,1.05e1.40) [OM to the other ARBs
Adjusted rate ratio- 2.49(95% CI,1.73e3.57),
P < 0.0001[for discharge diagnosis of intestinal
malabsorption- OM to other ARBS]

Table 2. Studies showing no signiﬁcant association Olmesartan (OM) and CSLE.
Study

Type of study

Biopsy proven
CSLE

Outcomes

Seng Chan Yu et al.11

Prospective cohort

No

Ruby Greywoode et al.12

Prospective cohort

yes

Peter Malfertheiner et al.13

Prospective cohort

No

Adjusted rate ratio- 0.33 (95% CI,0.10e1.09, P-0.070)
[OM to other ARBS]
No signiﬁcant history of diarrhea among OM users
undergoing EGDs and colonoscopy
RR:2.50, 95% CI,1.21e5.19, P-0.01 [incidence of CSLE
among ARBs and OM users]

CSLE and Celiac disease/sprue (CD/CS) share
common features like increase in aggregation of
CD8þ cells and overexpression of IL-8 to suggest a
possible immune mediated process. Delay in the
onset of symptoms after initiation of the offending
medication points towards cell-mediated immunity
damage rather than type-1 hypersensitivity reaction.
While Angiotensin receptors type-1 get saturated
with ARBs, circulating angiotensin-2 might bind
with type 2 receptors and trigger pro-apoptotic affects resulting in cell damage causing enteropathy
like picture.5

5. The controversy continues
The association between CSLE and the use of OM
was initially reported in a case series of 22 patients,1
followed by a small series of individual case reports.
A large observation study from France showed the
2.4 to 3-fold increased risk of hospitalization among
OM users with intestinal malabsorption (IM) and
CSLE when compared with other ARBs and ACEI.6
It also reported the prolonged median stay of 9-day
with OM use compared to 2 days in other ARBs use.
Recent case reports showed the possible association
between other ARBs and enteropathy-valsartan,
irbesratan, telmisartan, losartan etc. This ﬁnding has
suggested the class effect hypothesis.8 The observation cohort from Germany and Italy showed the
class effect of ARB for association with CSLE.9 It also
reported that the incidence rate of intestinal
malabsorption was relatively low among OM, other
ARBs and ACEI users (3.1, 8.8 and 2.3 per 100 person
years). In contrast to above mentioned studies, no
difference in the events of diarrhea or malabsorption was found between use of OM and the controls
in the large randomized controlled ROADMAP

trial.7 Further details of studies regarding the association are described in tables (Table 1 showing
association and Table 2 showing no association).
Few explanations for the conﬂicting results had
been proposed. There has been a concern for the
use of different ICD codes to describe unspeciﬁed
intestinal malabsorption or SLE or for the enrolment
of the patients. Many studies did not consider the
presence of the confounders (presence of Diabetes
in ROADMAP trial). There is a limited data on
outpatient scenario of CSLE or intestinal malabsorption among the ARBs or ACEI users. These
factors could explain difference in outcomes of
various studies.

6. Take home message
Considering the widespread use of Olmesartan,
and other ARBs and ACEI, even the low incidence of
Sprue-like enteropathy may have a signiﬁcant
impact on the patient population. All patients
receiving this group of medications should be
educated about the symptoms associated with
CSLE. All clinicians should be vigilant about the
clinical entity of CSLE and should consider discontinuation of the culprit agent for clinical and histological recovery in the affected patients.
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